A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs IMC CS4 (Primary) ; Durvalumab; Tremelimumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 12 Jul 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 12 Jul 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Jan 2018.
- 12 Jul 2016 Status changed from not yet recruiting to recruiting.